留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

多病共存与急性心肌梗死患者远期心力衰竭的相关性研究

陈芷倩 叶鑫瑛 钱焱 龚开政 赵培

陈芷倩, 叶鑫瑛, 钱焱, 龚开政, 赵培. 多病共存与急性心肌梗死患者远期心力衰竭的相关性研究[J]. 中华全科医学, 2023, 21(9): 1470-1473. doi: 10.16766/j.cnki.issn.1674-4152.003148
引用本文: 陈芷倩, 叶鑫瑛, 钱焱, 龚开政, 赵培. 多病共存与急性心肌梗死患者远期心力衰竭的相关性研究[J]. 中华全科医学, 2023, 21(9): 1470-1473. doi: 10.16766/j.cnki.issn.1674-4152.003148
CHEN Zhiqian, YE Xinying, QIAN Yan, GONG Kaizheng, ZHAO Pei. Correlation between multiple chronic conditions and long-term heart failure after acute myocardial infarction[J]. Chinese Journal of General Practice, 2023, 21(9): 1470-1473. doi: 10.16766/j.cnki.issn.1674-4152.003148
Citation: CHEN Zhiqian, YE Xinying, QIAN Yan, GONG Kaizheng, ZHAO Pei. Correlation between multiple chronic conditions and long-term heart failure after acute myocardial infarction[J]. Chinese Journal of General Practice, 2023, 21(9): 1470-1473. doi: 10.16766/j.cnki.issn.1674-4152.003148

多病共存与急性心肌梗死患者远期心力衰竭的相关性研究

doi: 10.16766/j.cnki.issn.1674-4152.003148
基金项目: 

国家自然科学基金资助项目 81970225

详细信息
    通讯作者:

    赵培,E-mail: zhaopei@yzu.edu.cn

  • 中图分类号: R542.22  R541.6

Correlation between multiple chronic conditions and long-term heart failure after acute myocardial infarction

  • 摘要:   目的  分析急性心肌梗死(AMI)患者远期心力衰竭(HF)的发生情况,并探讨多病共存(MCC)与其相关性。  方法  选择2016年1月—2018年12月在扬州大学附属医院心内科住院的AMI患者355例,根据结局分为心衰组(149例)和非心衰组(206例),中位随访时间为43.0个月。回顾性分析2组患者的基线资料;使用Kaplan-Meier分析和Cox回归分析评估MCC在AMI患者远期HF发生中的作用;运用Cochran-Armitage检验分析共存疾病数与AMI患者远期HF发生率的关系。  结果  (1) 心衰组患者年龄更大,左心室射血分数更低,GRACE评分及MCC占比更高。心衰组MCC发生率为非心衰组的1.6倍;(2)年龄(HR=1.024,95% CI: 1.003~1.045)、低左室射血分数(HR=0.963,95% CI: 0.946~0.980)、GRACE评分(HR=1.011,95% CI: 1.004~1.018)及MCC(HR=1.517,95% CI: 1.073~2.146)是AMI患者远期HF的独立影响因素;(3)MCC患者AMI后远期HF的发生率明显高于非MCC患者(P<0.05);(4)AMI患者远期HF发生率与共存疾病数呈正相关关系(P<0.05)。  结论  MCC是AMI患者远期HF的独立危险因素,对AMI患者远期HF的发生具有预测价值,且远期HF发生率随共存疾病数的增加而增高。

     

  • 图  1  MCC对AMI患者远期HF发生率的影响

    注:A为非多病共存组与多病共存组的远期HF发生率比较;B为无合并症组、一个合并症组和多个合并症组的远期HF发生率比较,其中,与多个合并症组比较,aP<0.05,bP < 0.01。

    Figure  1.  Effect of MCC on the incidence of long-term HF in AMI patients

    表  1  心衰组与非心衰组患者临床资料比较

    Table  1.   Comparison of clinical data between HF group and non-HF group

    项目 非心衰组(n=206) 心衰组(n=149) 统计量 P
    人口学特征
      年龄[M(P25, P75),岁] 60.0(51.0, 67.0) 70.0(61.0, 76.5) -6.361a < 0.001
      性别(男性/女性,例) 169/37 113/36 2.035b 0.154
    临床特征
      心率[M(P25, P75),次/min] 72.0(64.8, 80.3) 75.0(66.0, 85.5) -2.321a 0.020
      收缩压[M(P25, P75),mmHg] 135.5(120.0, 150.0) 130.0(120.0, 150.0) -1.094a 0.274
      舒张压[M(P25, P75),mmHg] 80.0(74.8, 94.3) 80.0(70.0, 90.0) -2.239a 0.025
      GRACE评分(x±s) 137.8±31.1 167.2±31.2 8.765c < 0.001
    实验室及器械检查
      红细胞(x±s,×1012/L) 4.70±0.53 4.60±0.58 -1.707c 0.089
      血红蛋白[M(P25, P75),g/L] 147.0(136.8, 157.0) 140.0(130.0, 154.0) -2.815a 0.005
      血小板[M(P25, P75),×109/L] 184.5(156.0, 226.0) 178.0(149.5, 213.5) -1.208a 0.227
      白细胞[M(P25, P75),×109/L] 8.6(7.3, 10.9) 9.1(7.2, 11.2) -0.920a 0.358
      血钾[M(P25, P75),mmol/L] 4.0(3.7, 4.2) 3.9(3.7, 4.3) -0.256a 0.798
      白蛋白[M(P25, P75),g/L] 41.7(39.4, 44.5) 40.5(37.5, 44.1) -2.450a 0.014
      总胆红素[M(P25, P75),μmol/L] 8.9(4.5, 13.5) 8.1(4.2, 14.7) -0.382a 0.702
      谷草转氨酶[M(P25, P75),U/L] 44.0(27.0, 91.3) 45.0(28.9, 92.5) -0.808a 0.419
      血糖[M(P25, P75),mmol/L] 7.5(6.1, 10.3) 8.3(6.4, 12.2) -2.077a 0.038
      肌酐[M(P25, P75),μmol/L] 72.8(62.0, 85.3) 75.0(63.0, 89.1) -1.362a 0.173
      甘油三酯[M(P25, P75),μmol/L] 1.8(1.3, 2.6) 1.4(1.1, 2.0) -4.662a < 0.001
      LDL-C[M(P25, P75),mmol/L] 2.3(1.9, 2.8) 2.3(1.9, 2.8) -0.101a 0.919
      D二聚体[M(P25, P75),mg/L] 0.2(0.1, 0.4) 0.4(0.2, 0.6) -5.302a < 0.001
      LVEF[M(P25, P75),%] 67.0(62.0, 70.0) 61.0(55.0, 67.0) -5.803a < 0.001
    既往史[例(%)]
      吸烟史 104(50.5) 64(43.0) 1.968b 0.161
      高血压史 139(67.5) 114(76.5) 3.446b 0.063
      糖尿病史 37(18.0) 48(32.2) 9.646b 0.002
      冠心病史 26(12.6) 36(24.2) 7.988b 0.005
      脑卒中史 20(9.7) 30(20.1) 7.766b 0.005
      高脂血症史 20(9.7) 7(4.7) 3.089b 0.079
      MCC 66(32.0) 78(52.3) 14.793b < 0.001
    院内治疗
      PCI治疗[例(%)] 177(85.9) 115(77.2) 4.526b 0.003
    注:aZ值,b为χ2值, ct值。LDL-C为低密度脂蛋白胆固醇。1 mmHg=0.133 kPa。
    下载: 导出CSV

    表  2  AMI患者远期HF影响因素的单因素Cox回归分析

    Table  2.   Univariate Cox regression analysis of long-term HF influencing factors in AMI patients

    项目 B SE Wald χ2 P HR 95% CI
    年龄 0.046 0.007 42.046 <0.001 1.048 1.033~1.062
    心率 0.012 0.005 5.218 0.022 1.012 1.002~1.023
    舒张压 -0.012 -0.006 4.556 0.033 0.988 0.977~0.999
    LVEF -0.052 0.008 42.236 <0.001 0.949 0.934~0.964
    血红蛋白 -0.012 0.004 10.706 0.001 0.988 0.981~0.995
    白蛋白 -0.051 0.018 7.960 0.005 0.950 0.917~0.984
    血糖 0.036 0.017 4.434 0.035 1.036 1.002~1.071
    甘油三酯 -0.285 0.085 11.135 0.001 0.752 0.636~0.889
    GRACE评分 0.018 0.002 71.379 <0.001 1.018 1.014~1.022
    D-二聚体 0.026 0.025 1.121 0.290 1.027 0.978~1.078
    PCI治疗 -0.302 0.196 2.384 0.123 0.739 0.504~1.085
    冠心病史 0.704 0.193 13.311 <0.001 2.021 1.385~2.950
    糖尿病史 0.625 0.176 12.558 <0.001 1.867 1.322~2.638
    脑卒中史 0.718 0.207 12.025 0.001 2.049 1.366~3.074
    MCC 0.668 0.165 16.376 <0.001 1.950 1.411~2.696
    下载: 导出CSV

    表  3  AMI患者远期HF影响因素的多因素Cox回归分析

    Table  3.   Multivariate Cox regression analysis of long-term HF influencing factors in AMI patients

    项目 B SE Wald χ2 P HR 95% CI
    年龄 0.024 0.011 2.268 0.023 1.024 1.003~1.045
    心率 0.005 0.006 0.803 0.422 1.005 0.993~1.017
    舒张压 0.011 0.007 1.549 0.121 1.011 0.997~1.025
    LVEF -0.038 0.009 -4.192 <0.001 0.963 0.946~0.980
    血红蛋白 -0.002 0.005 -0.278 0.781 0.998 0.988~1.009
    白蛋白 0.013 0.019 0.677 0.499 1.013 0.976~1.050
    血糖 0.019 0.019 1.030 0.303 1.019 0.983~1.058
    甘油三酯 -0.150 0.089 -1.684 0.092 0.861 0.724~1.025
    GRACE评分 0.011 0.004 2.984 0.003 1.011 1.004~1.018
    MCC 0.417 0.177 2.358 0.018 1.517 1.073~2.146
    下载: 导出CSV
  • [1] 娄逸, 钱菊英, 陈章炜, 等. 2型糖尿病对急性STEMI患者经皮冠状动脉介入治疗后炎症反应及远期心肌重构的影响[J]. 中国临床医学, 2019, 26(3): 398-405. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYX201903016.htm

    LOU Y, QIAN J Y, CHEN Z W, et al. The role of diabetes mellitus in inflammatory reaction and long-term cardiac remodeling in patients diagnosed with acute myocardial infarction underwent primary percutaneous coronary intervention[J]. Chinese Journal of Clinical, 2019, 26(3): 398-405. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYX201903016.htm
    [2] 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2021概要[J]. 中国循环杂志, 2022, 37(6): 553-578. doi: 10.3969/j.issn.1000-3614.2022.06.001

    The Writing Committee of the Report on Cardiovascular Health and Diseases in China. Report on Cardiovascular Health and Diseases in China 2021: an Updated Summary[J]. Chinese Circulation Journal, 2022, 37(6): 553-578. doi: 10.3969/j.issn.1000-3614.2022.06.001
    [3] SEFEROVIC P M, PIEPOLI M F, LOPATIN Y, et al. Heart Failure Association of the European Society of Cardiology Quality of Care Centres Programme: design and accreditation document[J]. Eur J Heart Fail, 2020, 22(5): 763-774. doi: 10.1002/ejhf.1784
    [4] 唐天娇, 曹立, 董碧蓉, 等. 老年人多病共存名词和定义专家共识(2022)[J]. 中华老年医学杂志, 2022, 41(9): 1028-1031. doi: 10.3760/cma.j.issn.0254-9026.2022.09.002

    TANG T J, CAO L, DONG B R, et al. Chinese expert consensus on the term and definition of multimorbidity in older adults(2022)[J]. Chinese Journal of Geriatrics, 2022, 41(9): 1028-1031. doi: 10.3760/cma.j.issn.0254-9026.2022.09.002
    [5] 甘勇, 杨婷婷, 杨宇迪, 等. 基于系统基模的慢性病主要危险因素分析及对策研究[J]. 中华全科医学, 2019, 17(12): 2046-2050, 2054. doi: 10.16766/j.cnki.issn.1674-4152.001124

    GAN Y, YANG T T, YANG Y D, et al. Analysis of main risk factors and countermeasures of chronic diseases based on systems archetypes[J]. Chinese Journal of General Practice, 2019, 17(12): 2046-2050, 2054. doi: 10.16766/j.cnki.issn.1674-4152.001124
    [6] MCMANUS D D, NGUYEN H L, SACZYNSKI J S, et al. Multiple cardiovascular comorbidities and acute myocardial infarction: temporal trends(1990-2007)and impact on death rates at 30 days and 1 year[J]. Clin Epidemiol, 2012, 2012: 115-123.
    [7] RINKMANN C, SCHOFER J. 4th universal definition of myocardial infarction 2018: what is new?[J]. Herz, 2018, 43(8): 681-688. doi: 10.1007/s00059-018-4763-6
    [8] 国家卫生计生委合理用药专家委员会, 中国药师协会. 心力衰竭合理用药指南(第2版)[J]. 中国医学前沿杂志(电子版), 2019, 11(7): 1-78. https://www.cnki.com.cn/Article/CJFDTOTAL-YXQY201907001.htm

    Committee of Exports on Rational Drug Use National Health and Family Planning Commission of The People's Republic of China; Chinese Pharmacists Association. Guidelines for rational use of drugs of heart failure(2 edition)[J]. Chinese Journal of the Frontiers of Medical Science(Electronic Version), 2019, 11(7): 1-78. https://www.cnki.com.cn/Article/CJFDTOTAL-YXQY201907001.htm
    [9] 廖显明, 王晓婕. 我国老年人慢性病共病的现状和应对策略[J]. 应用预防医学, 2022, 28(2): 191-194, 197. https://www.cnki.com.cn/Article/CJFDTOTAL-GXYX202202028.htm

    LIAO X M, WANG X L. Current situation and coping strategies of chronic comorbidities among the elderly in China[J]. Applied Preventive Medicine, 2022, 28(2): 191-194, 197. https://www.cnki.com.cn/Article/CJFDTOTAL-GXYX202202028.htm
    [10] ZHANG F Y, WONG C W, CHIU Y D, et al. Prognostic impact of comorbidity measures on outcomes following acute coronary syndrome: a systematic review[J]. Int J clin Pract, 2021, 75(10): e14345-e14345. DOI: 10.1111/ijcp.14345.
    [11] 严研, 公威, 王晓, 等. 多病共患的老年急性冠状动脉综合征患者抗栓治疗情况及预后分析[J]. 中华心血管病杂志, 2022, 50(5): 443-449.

    YAN Y, GONG W, WANG X, et al. Multimorbidity in elderly patients with acute coronary syndrome: insights from BleeMACS registry[J]. Chinese Journal of Cardiology, 2022, 50(5): 443-449.
    [12] LIU G H, XUE Y L, LIU Y H, et al. Multimorbidity in cardiovascular disease and association with life satisfaction: a Chinese national cross-sectional study[J]. BMJ Open, 2020, 10(12): e042950. DOI: 10.1136/BMJopen-2020-042950.
    [13] BREEN K, FINNEGAN L, VUCKOVIC K, et al. Multimorbidity in patients with acute coronary syndrome is associated with greater mortality, higher readmission rates, and increased length of stay: a systematic review[J]. J Cardiovasc Nurs, 2020, 35(6): E99-E110. DOI: 10.1097/JCN.0000000000000748.
    [14] HALL M, DONDO T B, YAN A T, et al. Multimorbidity and survival for patients with acute myocardial infarction in England and Wales: latent class analysis of a nationwide population-based cohort[J]. PLos Med, 2018, 15(3): e1002501. DOI: 10.1371/journal.pmed.1002501.
    [15] 黄萍, 汪铭涵, 张安, 等. 上海实施国家基本公共卫生服务项目十年效果评价[J]. 中华全科医学, 2020, 18(12): 1979-1983. doi: 10.16766/j.cnki.issn.1674-4152.001668

    HUANG P, WANG M R, ZHANG A, et al. Evaluation of the ten-year effect of implementing national basic public health services in Shanghai[J]. Chinese Journal of General Practice, 2020, 18(12): 1979-1983. doi: 10.16766/j.cnki.issn.1674-4152.001668
    [16] 胡月, 王雪莲. 高血压患者对家庭医生签约服务利用及效果评价[J]. 卫生软科学, 2019, 33(6): 53-57. https://www.cnki.com.cn/Article/CJFDTOTAL-WRKX201906011.htm

    HU Y, WANG X L. Study on the utilization and effect evaluation of family doctors' contract service in hypertensive[J]. Soft Science of Health, 2019, 33(6): 53-57. https://www.cnki.com.cn/Article/CJFDTOTAL-WRKX201906011.htm
    [17] 赖国彬. 全科医疗模式在照顾社区老年多病共存患者中的应用[J]. 中国社区医师, 2021, 37(11): 25-26. https://www.cnki.com.cn/Article/CJFDTOTAL-XCYS202111011.htm

    LAI G B. Application of general practice model in caring for elderly patients with multiple diseases in the community[J]. Chinese Community Doctors, 2021, 37(11): 25-26. https://www.cnki.com.cn/Article/CJFDTOTAL-XCYS202111011.htm
  • 加载中
图(1) / 表(3)
计量
  • 文章访问数:  164
  • HTML全文浏览量:  44
  • PDF下载量:  14
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-12-15
  • 网络出版日期:  2023-10-19

目录

    /

    返回文章
    返回